| Snowflake Score | |
|---|---|
| Valuation | 3/6 |
| Future Growth | 4/6 |
| Past Performance | 2/6 |
| Financial Health | 6/6 |
| Dividends | 2/6 |
Guangzhou Kingmed Diagnostics Group Co., Ltd. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | CN¥38.35 |
| 52 Week High | CN¥83.50 |
| 52 Week Low | CN¥37.91 |
| Beta | 0.52 |
| 1 Month Change | -30.41% |
| 3 Month Change | -28.45% |
| 1 Year Change | -52.12% |
| 3 Year Change | -72.30% |
| 5 Year Change | 12.79% |
| Change since IPO | 71.67% |
Recent News & Updates
Recent updates
Shareholder Returns
| 603882 | CN Healthcare | CN Market | |
|---|---|---|---|
| 7D | -9.0% | 3.3% | 3.1% |
| 1Y | -52.1% | -33.5% | -13.1% |
Return vs Industry: 603882 underperformed the CN Healthcare industry which returned -33.5% over the past year.
Return vs Market: 603882 underperformed the CN Market which returned -13.1% over the past year.
Price Volatility
| 603882 volatility | |
|---|---|
| 603882 Average Weekly Movement | 7.2% |
| Healthcare Industry Average Movement | 6.8% |
| Market Average Movement | 8.6% |
| 10% most volatile stocks in CN Market | 12.6% |
| 10% least volatile stocks in CN Market | 5.2% |
Stable Share Price: 603882's share price has been volatile over the past 3 months.
Volatility Over Time: 603882's weekly volatility (7%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2006 | 11,586 | Yaoming Liang | www.kingmed.com.cn |
Guangzhou Kingmed Diagnostics Group Co., Ltd. provides medical diagnosis services in China. The company also offers clinical research, health management, cold chain logistics, and scientific research services, as well as vitro diagnostics, big data, artificial intelligence, and forensic testing services.
Guangzhou Kingmed Diagnostics Group Co., Ltd. Fundamentals Summary
| 603882 fundamental statistics | |
|---|---|
| Market cap | CN¥17.82b |
| Earnings (TTM) | CN¥475.13m |
| Revenue (TTM) | CN¥8.26b |
37.5x
P/E Ratio2.2x
P/S RatioIs 603882 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 603882 income statement (TTM) | |
|---|---|
| Revenue | CN¥8.26b |
| Cost of Revenue | CN¥5.36b |
| Gross Profit | CN¥2.90b |
| Other Expenses | CN¥2.43b |
| Earnings | CN¥475.13m |
Last Reported Earnings
Mar 31, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | 1.02 |
| Gross Margin | 35.13% |
| Net Profit Margin | 5.75% |
| Debt/Equity Ratio | 5.3% |
How did 603882 perform over the long term?
See historical performance and comparison